Myasthenia gravis history and symptoms
Jump to navigation
Jump to search
|
Myasthenia gravis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myasthenia gravis history and symptoms On the Web |
|
American Roentgen Ray Society Images of Myasthenia gravis history and symptoms |
|
Risk calculators and risk factors for Myasthenia gravis history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Keanu Ngo[2]
History and Symptoms
Key historical features
- Fatigability and fluctuation are the characteristic historical clues to myasthenia gravis (MG): weakness worsens with sustained or repetitive use and improves with rest. Symptoms commonly fluctuate over the course of the day and from day to day, often becoming more prominent later in the day. Relevant examples include worsening ptosis or diplopia with reading or driving, fatigable chewing during a meal, difficulty climbing stairs or rising from a chair, and neck weakness later in the day.[1][2]
- Weakness is typically painless and not associated with sensory loss. Numbness, paresthesias, prominent pain, or other sensory symptoms should prompt consideration of an alternative or additional diagnosis.[3]
- Ask about the temporal pattern of symptoms: time of day, relationship to repetitive activity, recovery after rest or sleep, day-to-day variability, and whether previously normal activities become progressively difficult with continued use.
- Identify the initial symptom distribution. Ocular symptoms are common at onset, but bulbar, facial, axial, limb, and, rarely, respiratory symptoms may be the presenting manifestation.[2]
- Precipitants and aggravators to elicit include infection, heat, emotional stress, surgery, pregnancy or childbirth, medication changes, and drugs that can impair neuromuscular transmission. Acute worsening associated with these factors should raise concern for impending myasthenic crisis.[1]
- Associated autoimmune disease, particularly thyroid disease, should be elicited because autoimmune disorders commonly coexist with MG.[2]
Ocular symptoms
- Ptosis is commonly asymmetric and fluctuating. Patients may report eyelid drooping that becomes more apparent with prolonged visual activity or later in the day.
- Diplopia is variable in direction and severity because of fatigable extraocular muscle weakness. Patients may describe intermittent or shifting binocular diplopia that worsens with sustained visual activity.
- Ocular symptoms may occur alone or precede generalized weakness. Approximately 85% of patients present with ocular symptoms, while a minority have disease that remains purely ocular.[1][4]
- Most generalization from ocular MG occurs within the first 2 years, with higher risk and earlier generalization reported in AChR-antibody-positive disease.[1][5]
Bulbar and facial symptoms
- Dysarthria may become nasal or indistinct with prolonged speaking.
- Dysphagia may be fatigable and may cause choking, coughing during meals, or nasal regurgitation. Ask whether swallowing becomes more difficult as a meal progresses.
- Dysphonia or hoarseness may fluctuate with prolonged speaking.
- Fatigable chewing may cause difficulty completing a meal, particularly with tougher foods, and may contribute to reduced oral intake or weight loss.
- Facial weakness may manifest as reduced facial expression, difficulty smiling fully, or an appearance of compensatory facial muscle activation. Subtle facial weakness may be overlooked unless specifically elicited.[6]
- Bulbar symptoms without prominent ocular complaints can occur and may mimic other neurologic disorders; the temporal relationship to repetitive activity and rest is particularly important in the history.[2]
Axial, limb, and respiratory symptoms
- Neck weakness may cause difficulty holding the head upright or a "dropped head," often worsening later in the day.
- Limb weakness is commonly proximal and may present as difficulty climbing stairs, rising from a chair, lifting objects overhead, or maintaining the arms in an elevated position.
- Respiratory symptoms include exertional dyspnea and orthopnea. Respiratory weakness is less commonly the presenting complaint but is clinically important because it can progress to myasthenic crisis.[2][1]
- Ask specifically about cough strength, secretion clearance, swallowing, choking, orthopnea, and progressive dyspnea when symptoms are worsening, particularly when bulbar weakness accompanies respiratory complaints.
Symptoms by clinical subgroup
- Ocular MG — weakness is confined to the extraocular muscles and/or levator palpebrae. Persistence of purely ocular disease beyond approximately 2 years is associated with a substantially lower subsequent risk of generalization, although this is not an absolute rule.[1][7]
- AChR-antibody-positive generalized MG commonly begins with ocular symptoms and may subsequently involve bulbar, facial, axial, limb, and respiratory muscles.[1]
- MuSK MG has a characteristic clinical pattern with prominent bulbar, facial, neck, and respiratory weakness. Facial and tongue wasting may occur, ocular involvement may be less prominent or diminish over time, and response to acetylcholinesterase inhibitors may be limited.[8][9]
Red flags and history that changes urgency
- Progressive dysphagia, choking, dysarthria, or inability to manage oral secretions should prompt urgent assessment for significant bulbar weakness.
- New or worsening dyspnea, orthopnea, weak cough, secretion retention, or rapidly progressive generalized weakness should raise concern for respiratory muscle involvement and possible myasthenic crisis.[1]
- Rapid symptom progression after infection, surgery, pregnancy or childbirth, medication changes, or exposure to drugs that impair neuromuscular transmission should increase concern for acute deterioration.[1]
- Sensory symptoms, pupillary abnormalities, or fixed focal neurologic deficits are atypical for MG and should prompt evaluation for an alternative or additional neurologic disorder.[3]
High-yield clinical pearls
- Ask specifically about activity-dependent fluctuation. Patients may not volunteer fatigability unless asked about symptoms at the end of the day or after repeated use.
- Ask about function rather than weakness alone. Difficulty finishing a meal, reading, driving because of diplopia, climbing stairs, rising from a chair, or keeping the head upright can reveal clinically important fatigability.
- Do not assume a fixed distribution of weakness. MG may involve different muscle groups over time, with ocular, bulbar, axial, limb, and respiratory symptoms occurring in varying combinations.[8]
- Do not dismiss subtle facial weakness. Reduced facial expression or incomplete smiling may be the patient's most noticeable generalized manifestation.[6]
- Do not miss respiratory symptoms. Dyspnea and orthopnea may be underreported despite clinically important respiratory muscle weakness.[2]
- Seronegative status does not exclude a clinically typical MG history. Clinical presentation should not be dismissed solely because prior antibody testing was negative; interpretation of serology belongs in Laboratory Findings.[2]
Common pitfalls
- Attributing symptoms to a fixed neurologic deficit rather than recognizing fluctuation with activity and rest.
- Assuming ocular-only symptoms will remain ocular. Most generalization occurs within the first 2 years, particularly in AChR-antibody-positive disease.[1][5]
- Missing isolated or predominant bulbar MG because ocular symptoms are absent or subtle.[2]
- Overlooking respiratory symptoms when the patient primarily reports dysphagia, dysarthria, or generalized fatigue.
- Attributing sensory complaints to MG. Sensory loss, paresthesias, or pupillary abnormalities are not characteristic features and warrant evaluation for another process.[3]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Punga AR; Maddison P; Heckmann JM; Guptill JT; Evoli A (2022). "Epidemiology, Diagnostics, and Biomarkers of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 176–188. doi:10.1016/S1474-4422(21)00297-0. PMID 35065040 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Meriggioli MN; Sanders DB (2009). "Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity". The Lancet Neurology. 8 (5): 475–490. doi:10.1016/S1474-4422(09)70063-8. PMID 19375665.
- ↑ 3.0 3.1 3.2 Gilhus NE (2016). "Myasthenia Gravis". The New England Journal of Medicine. 375 (26): 2570–2581. doi:10.1056/NEJMra1602678.
- ↑ Manolopoulos A; Alzuabi M; Elmashala A; et al. (2025). "Immunoglobulin for Myasthenia Gravis". The Cochrane Database of Systematic Reviews. 2025 (10): CD013801. doi:10.1002/14651858.CD013801.pub2.
- ↑ 5.0 5.1 Fang CEH; Bokre D; Wong SH (2023). "Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: A Systematic Review and Meta-Analysis". Neurology. 101 (16): e1594–e1605. doi:10.1212/WNL.0000000000207642. PMID 37643888 Check
|pmid=value (help). - ↑ 6.0 6.1 Keesey JC (2004). "Clinical evaluation and management of myasthenia gravis". Muscle & Nerve. 29 (4): 484–505. doi:10.1002/mus.20030.
- ↑ Kamarajah SK; Sadalage G; Palmer J; et al. (2018). "Ocular Presentation of Myasthenia Gravis: A Natural History Cohort". Muscle & Nerve. 57 (4): 622–627. doi:10.1002/mus.25971.
- ↑ 8.0 8.1 Huijbers MG; Marx A; Plomp JJ; Le Panse R; Phillips WD (2022). "Advances in the Understanding of Disease Mechanisms of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 163–175. doi:10.1016/S1474-4422(21)00357-4. PMID 35065039 Check
|pmid=value (help). - ↑ Gilhus NE; Verschuuren JJ (2015). "Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies". The Lancet Neurology. 14 (10): 1023–1036. doi:10.1016/S1474-4422(15)00145-3. PMID 26376969.